Last $5.94 USD
Change Today +0.035 / 0.59%
Volume 1.4M
As of 3:32 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

immunogen inc (IMGN) Snapshot

Open
$5.90
Previous Close
$5.90
Day High
$6.03
Day Low
$5.81
52 Week High
02/24/14 - $17.80
52 Week Low
12/23/14 - $5.34
Market Cap
510.1M
Average Volume 10 Days
3.4M
EPS TTM
$-0.97
Shares Outstanding
85.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOGEN INC (IMGN)

immunogen inc (IMGN) Related Businessweek News

No Related Businessweek News Found

immunogen inc (IMGN) Details

ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates include IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia. The company also develops compounds, such as AMG 172 that is in Phase I clinical trials for the treatment of clear cell renal cell carcinoma; AMG 595, which is in Phase I clinical trials for treating glioblastoma; BAY 94-9343 is in early clinical trials for the treatment of mesothelioma and ovarian cancer; BT-062 for multiple myeloma; SAR3419, which has completed Phase II clinical trials for the treatment of diffuse large B-cell lymphoma; SAR650984 that is in early clinical trials for the treatment of multiple myeloma; SAR566658 that is in Phase I clinical trials for treating CA6-positive solid tumors; and SAR408701 for solid tumors. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; the Roche Group; and Sanofi. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

307 Employees
Last Reported Date: 08/28/14
Founded in 1981

immunogen inc (IMGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $544.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $245.0K
Chief Development Officer and Executive Vice ...
Total Annual Compensation: $432.4K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $377.2K
Vice President, General Counsel and Secretary
Total Annual Compensation: $297.3K
Compensation as of Fiscal Year 2014.

immunogen inc (IMGN) Key Developments

ImmunoGen, Inc. Announces Executive Changes, Effective January 5, 2015

ImmunoGen, Inc. announced the appointment of Richard J. Gregory, Ph.D., as executive vice president, Research and chief scientific officer (CSO), reporting to ImmunoGen president and CEO, Daniel Junius. Dr. Gregory will join the company on January 5, 2015, at which time current CSO, John Lambert, Ph.D., will assume the position of executive vice president, distinguished research fellow. Dr. Gregory brings to ImmunoGen deep scientific and research management experience, most recently serving as senior vice president and head of research for the Sanofi Genzyme Research & Development Center. Dr. Gregory has over twenty-five years of scientific and research management experience, most of it gained in positions of increasing responsibility at Genzyme. In 2003, he was appointed the head of research at Genzyme, with responsibility for early research – from discovery to development – for all Genzyme therapeutic areas, including an ADC initiative. Following Sanofi’s acquisition of Genzyme in 2011, Dr. Gregory was appointed head of the Sanofi-Genzyme R&D Center and in that capacity was responsible for Genzyme R&D from discovery through regulatory approval. Dr. Gregory succeeds Dr. Lambert, who joined ImmunoGen in 1987 and has been the company’s CSO since 2008. Dr. Lambert assumes the newly created role of executive vice president, distinguished research fellow and remains a member of ImmunoGen’s executive team, reporting to Mr. Junius.

ImmunoGen, Inc. Announces Encouraging IMGN529 Clinical Data at 56th ASH Annual Meeting and Exposition

ImmunoGen, Inc. announced the presentation of encouraging clinical findings with its IMGN529 experimental therapy for B-cell malignancies at the American Society of Hematology (ASH) annual meeting. These include objective responses at doses that were generally well tolerated. ImmunoGen's IMGN529 is a potential new treatment for DLBCL and other non-Hodgkin lymphoma (NHL) subtypes. An ADC, it comprises an antibody that targets CD37, found on B-cell malignancies, with the potent cancer cell-killing agent, DM1, attached. The antibody serves to deliver the DM1 specifically to B cells to kill them and, based on preclinical research, also contributes anticancer activity. IMGN529 is currently in the dose-finding portion of a Phase I clinical trial, which assesses increasing doses of this experimental therapy in new groups of patients with relapsed/refractory NHL. Findings with the first doses evaluated were reported previously. The IMGN529 dose levels evaluated to date range from 0.1 to 1.4 mg/kg, administered once every three weeks. Its MTD has not yet been established, and evaluation of the 1.4 mg/kg level is ongoing. 24 of the 33 patients enrolled to date were evaluable for efficacy. Ten evaluable patients had DLBCL, which had been heavily pretreated, and four (40%) of these patients had an objective response: one had a complete response (CR) and three had partial responses (PRs). The CR and one of the PRs were among patients treated with 1.0 mg/kg, a high IMGN529 dose level to complete evaluation to date. Both of these patients had received multiple prior treatments, including autologous stem cell transplant (ASCT). Ten of the 24 evaluable patients had follicular lymphoma and one of these patients also had a PR. This patient, too, had received multiple treatments including ASCT.

Ventana Medical Systems, Inc. Announces Collaboration to Develop Companion Diagnostics for ImmunoGen, Inc.'s Targeted Anticancer Agents

Ventana Medical Systems, Inc. announced it has entered into an agreement with ImmunoGen, Inc. to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry (IHC) test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha (FRa, also known as folate receptor 1, or FOL1) that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate (ADC). Cancers that highly express FRa include epithelial ovarian cancer, endometrial cancer, and types of non-small cell lung cancers (NSCLC). The goal of the collaboration is to leverage Ventana's expertise in companion diagnostic development, from prototyping through regulatory approval and commercialization, to identify specific patient populations for ImmunoGen's bio-target directed therapies. This pharma collaboration is one of dozens currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tools that help identify those individuals who are most likely to benefit from specific treatments. In addition to ImmunoGen, Ventana has announced collaborations with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMGN:US $5.94 USD +0.035

IMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.19 EUR +0.14
Abzena PLC 78.50 GBp 0.00
BioInvent International AB kr2.73 SEK +0.20
Genmab A/S kr354.30 DKK -6.10
MorphoSys AG €76.28 EUR -0.484
View Industry Companies
 

Industry Analysis

IMGN

Industry Average

Valuation IMGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.1x
Price/Book 8.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOGEN INC, please visit www.immunogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.